Skip to main content
Media Hub

Press Releases

For all press and media enquiries please contact mediarelations@chiesi.com 

  • Corporate

    Europe approves Holoclar, the first stem-cell medicine

    The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar ®, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea damage. Holoclar ® is manufactured by Holostem Terapie…

  • Corporate

    Chiesi's extra-fine inhaler for persistent asthma

    The first extra-fine dry powder inhaler was successfully launched in Italy on October 2013 to address the unmet doctors’ and patients’ need of a user-friendly and safe drug delivery device. Being an high quality alternative to the pressurised metered dose inhaler, this innovative device can deliver…